Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Abbott Laboratories
(NYSE:ABT)
Intraday
$106.37
-1.22
[-1.13%]
After-Hours
$106.37
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$106.37
-1.22
[-1.13%]
At close: Apr 24
$106.37
0
[0.00%]
After Hours: 6:19PM EDT
Get Report
Watch
Q1 2024 Earnings were released on Wed Apr 17th, before the market open
The most recent conference call was at 9:00 AM, 7 days ago
Click to view past webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Abbott Laboratories Stock (NYSE:ABT)
Abbott Laboratories Stock (NYSE: ABT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 22, 2024
Barclays Maintains Overweight on Abbott Laboratories, Lowers Price Target to $140
Benzinga Newsdesk
-
2 days ago
Thursday, April 18, 2024
Behind the Scenes of Abbott Laboratories's Latest Options Trends
Benzinga Insights
-
6 days ago
RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125
Benzinga Newsdesk
-
6 days ago
Wednesday, April 17, 2024
Stocks Fall As Geopolitics, Economic Worries Spook Investors, Chipmakers Sell Off, Bitcoin Tumbles To $60,000: What's Driving Markets Wednesday?
Piero Cingari
-
Apr 17, 2024, 2:09PM
Abbott shares are trading lower following Q1 earnings.
Benzinga Newsdesk
-
Apr 17, 2024, 10:23AM
Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings
Avi Kapoor
-
Apr 17, 2024, 10:07AM
Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance
Vandana Singh
-
Apr 17, 2024, 8:42AM
Abbott Forecasts Q2 2024 Adjusted EPS Of $1.08-$1.12 Versus Consensus Of $1.12
Benzinga Newsdesk
-
Apr 17, 2024, 7:37AM
Abbott Revises 2024 Adjusted EPS Guidance To $4.55-$4.70 Versus Prior Guidance Of $4.50-$4.70 And Consensus Of $4.62
Benzinga Newsdesk
-
Apr 17, 2024, 7:36AM
Abbott Laboratories Q1 2024 Adj EPS $0.98 Beats $0.95 Estimate, Sales $9.964B Beat $9.880B Estimate
Benzinga Newsdesk
-
Apr 17, 2024, 7:32AM
Wall Street Poised To Rebound From Slump As Earnings Optimism Grows: Analyst Eyes This S&P 500 Level As Attractive Entry Point
Shanthi Rexaline
-
Apr 17, 2024, 7:09AM
Earnings Scheduled For April 17, 2024
Benzinga Insights
-
Apr 17, 2024, 5:15AM
Investor Optimism Decreases; Dow Ends 6-Session Losing Streak
Avi Kapoor
-
Apr 17, 2024, 2:06AM
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
Avi Kapoor
-
Apr 17, 2024, 2:06AM
Monday, April 15, 2024
Abbott/Thoratec Corp. Recalls HeartMate II And HeartMate 3 Left Ventricular Assist System Due To Long-term Buildup Causing An Obstruction
Benzinga Newsdesk
-
Apr 15, 2024, 11:26AM
Friday, April 12, 2024
Jim Cramer Calls Cummins 'Terrific,' Recommends Selling This Chinese Auto Manufacturer
Avi Kapoor
-
Apr 12, 2024, 8:43AM
Thursday, April 11, 2024
Abbott Laboratories Unusual Options Activity
Benzinga Insights
-
Apr 11, 2024, 2:31PM
Tuesday, April 09, 2024
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
Avi Kapoor
-
Apr 9, 2024, 9:10AM
Thursday, April 04, 2024
Evercore ISI Group Maintains Outperform on Abbott Laboratories, Raises Price Target to $125
Benzinga Newsdesk
-
Apr 4, 2024, 12:18PM
Wednesday, April 03, 2024
Analyst Ratings For Abbott Laboratories
Benzinga Insights
-
Apr 3, 2024, 12:00PM
Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $128
Benzinga Newsdesk
-
Apr 3, 2024, 11:32AM
Tuesday, April 02, 2024
FDA Approves Abbott's Heart Valve Repair Device For Patients At Risk Of Complications/Death During Open-Heart Surgeries
Vandana Singh
-
Apr 2, 2024, 1:00PM
Abbott Receives FDA Approval For TriClip, First-Of-Its-Kind Device To Repair Leaky Tricuspid Heart Valve
Benzinga Newsdesk
-
Apr 2, 2024, 9:01AM
Monday, April 01, 2024
Abbott Receives FDA Clearance For Whole Blood Rapid Test To Help With Assessment Of Concussion At The Patient's Bedside
Benzinga Newsdesk
-
Apr 1, 2024, 9:01AM
Thursday, March 28, 2024
How Is The Market Feeling About Abbott Laboratories?
Benzinga Insights
-
Mar 28, 2024, 2:00PM
Wednesday, March 27, 2024
Performance Comparison: Abbott Laboratories And Competitors In Health Care Equipment & Supplies Industry
Benzinga Insights
-
Mar 27, 2024, 11:00AM
Tuesday, March 19, 2024
What the Options Market Tells Us About Abbott Laboratories
Benzinga Insights
-
Mar 19, 2024, 10:16AM
Friday, March 15, 2024
What's Going On With Abbott Laboratories Stock On Friday?
Vandana Singh
-
Mar 15, 2024, 1:48PM
Abbott shares are trading lower after rival Reckitt Benckiser was ordered to pay $60 million in its baby formula case.
Benzinga Newsdesk
-
Mar 15, 2024, 12:51PM
Monday, March 11, 2024
FDA Says Abbott Recalls Heartmate Touch Communication System For Unintentional Pump Start And Stop; Recalling Their Heartmate Touch System (Version 1.0.32) For Risk Of Unexpected Pump Stop Or Start; Identified Heartmate Touch Communication System Recall As Class I Recall And 8 Reported Injuries, No Reports Of Death
Benzinga Newsdesk
-
Mar 11, 2024, 3:49PM
Friday, March 08, 2024
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Benzinga Insights
-
Mar 8, 2024, 4:00PM
Wednesday, March 06, 2024
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's
Vandana Singh
-
Mar 6, 2024, 4:48PM
Abbott Annonuces Data From Two Real-World Studies Showing People With Type 2 Diabetes Using GLP-1 Medicines Saw Improvement In Their HbA1C After Adding Freestyle Libre Technology To Their Regimen
Benzinga Newsdesk
-
Mar 6, 2024, 9:03AM
Tuesday, March 05, 2024
Sell Alert: John A. McCoy Jr. Cashes Out $55K In Abbott Laboratories Stock
Benzinga Insights
-
Mar 5, 2024, 10:02AM
Executive Vice President Of Abbott Laboratories Sold $94K In Stock
Benzinga Insights
-
Mar 5, 2024, 10:02AM
Massive Insider Trade At Abbott Laboratories
Benzinga Insights
-
Mar 5, 2024, 10:02AM
Friday, March 01, 2024
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Benzinga Insights
-
Mar 1, 2024, 11:30AM
Monday, February 26, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Feb 26, 2024, 12:35PM
Friday, February 23, 2024
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment
Benzinga Insights
-
Feb 23, 2024, 12:45PM
Tuesday, February 20, 2024
Peering Into Abbott Laboratories's Recent Short Interest
Benzinga Insights
-
Feb 20, 2024, 1:30PM
Wednesday, February 14, 2024
Cardiology's Quantum Leap: FDA's Advisory Panel Gives Thumbs Up To Abbott's Minimally Invasive Heart Valve Repair Device
Vandana Singh
-
Feb 14, 2024, 12:47PM
RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $128 Price Target
Benzinga Newsdesk
-
Feb 14, 2024, 9:50AM
Reported Late Tuesday, FDA Advisory Committee Votes In Favor Of Abbott's First-of-Its-Kind TriClip™ System To Treat People With A Leaky Tricuspid Heart Valve
Benzinga Newsdesk
-
Feb 14, 2024, 1:25AM
Monday, February 12, 2024
FDA Advisors Set To Discuss Abbott's TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom
Vandana Singh
-
Feb 12, 2024, 11:00AM
Thursday, February 08, 2024
This Is What Whales Are Betting On Abbott Laboratories
Benzinga Insights
-
Feb 8, 2024, 11:32AM
Wednesday, February 07, 2024
Insulet Has Received CE Mark Approval Under The European Medical Device Regulation For The Added Compatibility Of The Abbott FreeStyle Libre 2 Plus Sensor With Insulet's Omnipod 5 Automated Insulin Delivery System For Individuals Aged Two Years And Older
Benzinga Newsdesk
-
Feb 7, 2024, 6:42AM
Saturday, February 03, 2024
Abbott Faces Lawsuit As Grandmother Questions PediaSure's Height Growth Claims
Nabaparna Bhattacharya
-
Feb 3, 2024, 3:03PM
Wednesday, January 31, 2024
Abbott Launches PROTALITY Brand
Benzinga Newsdesk
-
Jan 31, 2024, 9:04AM
Tuesday, January 30, 2024
Looking At Abbott Laboratories's Recent Unusual Options Activity
Benzinga Insights
-
Jan 30, 2024, 12:01PM
Friday, January 26, 2024
Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $141
Benzinga Newsdesk
-
Jan 26, 2024, 1:22PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch